-+ 0.00%
-+ 0.00%
-+ 0.00%
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Share
Listen to the news

            Positive safety and favourable biodistribution seen in all subjects dosed

Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending